October 23, 2012
Company news: Eli Lilly
Eli Lilly said its Phase III AWARD trials for its weekly dulaglutide GLP-1 drug, in testing for type 2 diabetes, met primary efficacy endpoints and demonstrated superiority for HbA1c lowering over exenatide and metformin. The most frequently reported adverse events were gastrointestinal-related and consistent with prior studies, said the company. A number of additional studies are ongoing as part of the AWARD battery.